Andrew T Miller1, Patricia Kruger2, Karen Conner3, Teresa Robertson4, Braden Rowley4, William Sause5, John C Ruckdeschel6, Denitza P Blagev7. 1. Department of Internal Medicine, Intermountain Medical Center, Murray, Utah. 2. Division of Oncology, Intermountain Medical Center, Murray, Utah. 3. Department of Radiology, Intermountain Medical Center, Murray, Utah. 4. Clinical Information Systems, Intermountain Medical Center, Murray, Utah. 5. Division of Radiation Oncology, Intermountain Medical Center, Murray, Utah. 6. Division of Oncology, Intermountain Medical Center, Murray, Utah; Synergy Cancer Center, Las Vegas, Nevada. 7. Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah; Division of Pulmonary and Critical Care Medicine, University of Utah, Salt Lake City, Utah. Electronic address: denitza.blagev@imail.org.
Abstract
PURPOSE: Lung cancer screening with low-dose CT (LDCT) demonstrated reduced mortality in the National Lung Screening Trial, yet there is debate as to whether the reported efficacy can translate into comparable effectiveness with community-based screening. The authors' purpose is to report the baseline patient characteristics and malignancy rate in the first 18 months after implementing a lung cancer screening program in an integrated community health system. METHODS: Patients were screened at 1 of 10 participating community-based centers within a 22-hospital system from 2013 to 2015. LDCT examinations were interpreted by 1 of 20 radiologists using structured reporting and an internally developed tracking system. Manual chart review was performed to ascertain the malignancy detection rate. RESULTS: A total of 357 patients were screened with LDCT. Of these, 80 patients were ineligible and 3 declined enrollment. The remaining 274 patients satisfied accepted screening criteria and were enrolled in the program. Malignancy was detected in a total of 11 enrollees (4.0%), 8 with lung cancer and 3 with extrapulmonary primary malignancies. Three patients (1.1%) were diagnosed with early-stage lung cancer and received definitive therapy. CONCLUSIONS: Early-stage lung cancer was detected with LDCT screening in an integrated community health system at a rate similar to other trials.
PURPOSE:Lung cancer screening with low-dose CT (LDCT) demonstrated reduced mortality in the National Lung Screening Trial, yet there is debate as to whether the reported efficacy can translate into comparable effectiveness with community-based screening. The authors' purpose is to report the baseline patient characteristics and malignancy rate in the first 18 months after implementing a lung cancer screening program in an integrated community health system. METHODS:Patients were screened at 1 of 10 participating community-based centers within a 22-hospital system from 2013 to 2015. LDCT examinations were interpreted by 1 of 20 radiologists using structured reporting and an internally developed tracking system. Manual chart review was performed to ascertain the malignancy detection rate. RESULTS: A total of 357 patients were screened with LDCT. Of these, 80 patients were ineligible and 3 declined enrollment. The remaining 274 patients satisfied accepted screening criteria and were enrolled in the program. Malignancy was detected in a total of 11 enrollees (4.0%), 8 with lung cancer and 3 with extrapulmonary primary malignancies. Three patients (1.1%) were diagnosed with early-stage lung cancer and received definitive therapy. CONCLUSIONS: Early-stage lung cancer was detected with LDCT screening in an integrated community health system at a rate similar to other trials.
Authors: Ji Won Lee; Hyae Young Kim; Jin Mo Goo; Eun Young Kim; Soo Jung Lee; Tae Jung Kim; Yeol Kim; Juntae Lim Journal: Korean J Radiol Date: 2018-06-14 Impact factor: 3.500